Still struggling to turn its manufacturing around, Dr. Reddy's is recalling 569,000 store-brand famotidine tablets in the U.S.
With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.
Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.
Ex-Lilly exec Alex Azar may nab the top job at HHS, where he could help pharma navigate some turbulent political waters.
Bristol-Myers aims to get its I-O med Opdivo to cancer patients as early as possible, and a new approval in melanoma would be a step in that direction.
Canada has become the first country to approve GlaxoSmithKline's Shingrix, a shingles vaccine that's key to the pharma giant's sales growth.
After stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye medication Restasis.
FDA reviewers flagged data on cardiovascular benefits—and potential eye risks—posed by Novo Nordisk's semaglutide, up for approval later this year.
A recent investigation alleges that Avanir Pharmaceuticals inappropriately marketed its neurological treatment Nuedexta to nursing home residents.
Bracing for generic competition to big-selling Lyrica, Pfizer has won FDA approval for a longer-lasting version that could help it defend sales.